Palbociclib resistance management

Palbociclib (Palbociclib) has been approved by the U.S. Food and Drug Administration for the first-line treatment of HR+/HER2 breast cancer. The resistance mechanisms of CDK4/6 inhibitors can be divided into cell cycle-specific resistance and cell cycle-non-specific resistance. Endocrine therapy combined with CDK4/6 inhibitorsTreatment with CDK4/6 inhibitors has become an internationally recommended treatment option for advanced breast cancer without visceral risk. For cancers that are resistant to drug resistance, chemotherapy is usually chosen as the follow-up treatment option in clinical practice. In the PALOMA-3 clinical study, most of the patients received fluorine. Patients treated with Sitran combined with palbociclib showed disease progression, and more than one-third of the patients received subsequent chemotherapy. The chemotherapy drugs used were capecitabine and taxanes. Combined targeted therapy is also a commonly used combination method in clinical practice and can also help delay the occurrence of drug resistance. However, everyone has a different constitution and has different drug resistance responses. If you feel unwell, please inform your doctor in time.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 tablets per box, sold overseas may be around RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by Bangladesh pharmaceutical factory may be around 900 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.